King Pharmaceuticals Announces Date for Release Of First Quarter 2001 Earnings

Apr 02, 2001, 01:00 ET from King Pharmaceuticals, Inc.

    BRISTOL, Tenn., April 2 /PRNewswire/ --
     King Pharmaceuticals, Inc. (NYSE:   KG) reported today that the company
 plans to announce earnings for the first quarter ending March 31, 2001, prior
 to the market open on April 30, 2001.  Conference call information will be
 provided when available via a subsequent press release.
     (Photo: http://www.newscom.com/cgi-bin/prnh/20010125/KGLOGO )
     King, headquartered in Bristol, Tennessee, is a vertically integrated
 pharmaceutical company that manufactures, markets, and sells primarily branded
 prescription pharmaceutical products.  King seeks to capitalize on niche
 opportunities in the pharmaceutical industry created by cost containment
 initiatives and consolidation among large global pharmaceutical companies.
 King's strategy is to acquire branded pharmaceutical products and to increase
 their sales by focused promotion and marketing and through product life cycle
 management.
 
 

SOURCE King Pharmaceuticals, Inc.
    BRISTOL, Tenn., April 2 /PRNewswire/ --
     King Pharmaceuticals, Inc. (NYSE:   KG) reported today that the company
 plans to announce earnings for the first quarter ending March 31, 2001, prior
 to the market open on April 30, 2001.  Conference call information will be
 provided when available via a subsequent press release.
     (Photo: http://www.newscom.com/cgi-bin/prnh/20010125/KGLOGO )
     King, headquartered in Bristol, Tennessee, is a vertically integrated
 pharmaceutical company that manufactures, markets, and sells primarily branded
 prescription pharmaceutical products.  King seeks to capitalize on niche
 opportunities in the pharmaceutical industry created by cost containment
 initiatives and consolidation among large global pharmaceutical companies.
 King's strategy is to acquire branded pharmaceutical products and to increase
 their sales by focused promotion and marketing and through product life cycle
 management.
 
 SOURCE  King Pharmaceuticals, Inc.